Claudia Paulmann

Title: Claudia Paulmann: Innovator in Immunotherapy

Introduction

Claudia Paulmann is a prominent inventor based in Mainz, Germany. She has made significant contributions to the field of immunotherapy, particularly through her innovative work on monoclonal antibodies. Her research focuses on the programmed death-1 (PD-1) protein, which plays a crucial role in regulating immune responses.

Latest Patents

Claudia Paulmann holds a patent for "Monoclonal antibodies directed against programmed death-1 protein and their use in medicine." This patent describes antibodies that can bind to the PD-1 protein, including human PD-1. The antibodies feature modifications in the Fc region that eliminate or reduce Fc-mediated effector functions. The patent also covers compositions or kits containing these antibodies or nucleic acids, emphasizing their application in immunotherapy, particularly for cancer treatment. Furthermore, the invention outlines methods for inducing an immune response in subjects using these antibodies or nucleic acids.

Career Highlights

Throughout her career, Claudia has worked with notable companies such as BioNTech SE and Genmab A/S. Her experience in these organizations has allowed her to contribute to groundbreaking advancements in the field of medicine.

Collaborations

Claudia has collaborated with esteemed colleagues, including Ugur Sahin and Sina Fellermeier-Kopf. These partnerships have further enhanced her research and development efforts in immunotherapy.

Conclusion

Claudia Paulmann is a trailblazer in the field of immunotherapy, with her innovative patent on monoclonal antibodies showcasing her commitment to advancing medical science. Her work continues to have a significant impact on cancer treatment and immune response modulation.